SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with Castle Biosciences

Reuters

Sep 23, 2025

SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with <a href="https://laohu8.com/S/CSTL">Castle Biosciences</a>

SciBase Holding AB announced that it has received an initial order for a clinical study from Castle Biosciences. This development follows a collaboration and license agreement between the two companies, which was announced on June 16, 2025. The collaboration aims to develop a test for predicting flares in patients with atopic dermatitis. The order pertains to products intended for use in the clinical study of this project, with deliveries set to commence in the fourth quarter. Castle Biosciences has also invested in SciBase, becoming its second largest shareholder. SciBase CEO Pia Renaudin expressed the company's enthusiasm for advancing the project in collaboration with Castle Biosciences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20250922:BIT:1083:0) on September 23, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569399761"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569399761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569399761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569399761","market":"us","top_or_hot":-1,"title":"SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with Castle Biosciences","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with <a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SciBase Holding AB announced that it has received an initial order for a clinical study from Castle Biosciences. This development follows a collaboration and license agreement between the two companies, which was announced on June 16, 2025. The collaboration aims to develop a test for predicting flares in patients with atopic dermatitis. The order pertains to products intended for use in the clinical study of this project, with deliveries set to commence in the fourth quarter. Castle Biosciences has also invested in SciBase, becoming its second largest shareholder. SciBase CEO Pia Renaudin expressed the company's enthusiasm for advancing the project in collaboration with Castle Biosciences.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20250922:BIT:1083:0) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with Castle Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with Castle Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with <a href=\"https://laohu8.com/S/CSTL\">Castle Biosciences</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SciBase Holding AB announced that it has received an initial order for a clinical study from Castle Biosciences. This development follows a collaboration and license agreement between the two companies, which was announced on June 16, 2025. The collaboration aims to develop a test for predicting flares in patients with atopic dermatitis. The order pertains to products intended for use in the clinical study of this project, with deliveries set to commence in the fourth quarter. Castle Biosciences has also invested in SciBase, becoming its second largest shareholder. SciBase CEO Pia Renaudin expressed the company's enthusiasm for advancing the project in collaboration with Castle Biosciences.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20250922:BIT:1083:0) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSTL","symbol_name":"Castle Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL16ynDh:1","article_id":"2569399761","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569399761","pubTimestamp":1758607242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SciBase Holding AB announced that it has received an initial order for a clinical study from Castle Biosciences. This development follows a collaboration and license agreement between the two companies, which was announced on June 16, 2025. The collaboration aims to develop a test for predicting flares in patients with atopic dermatitis. The order pertains to products intended for use in the clinical study of this project, with deliveries set to commence in the fourth quarter. Castle Biosciences has also invested in SciBase, becoming its second largest shareholder. SciBase CEO Pia Renaudin expressed the company's enthusiasm for advancing the project in collaboration with Castle Biosciences.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSTL":"Castle Biosciences, Inc.","BK4196":"保健护理服务"},"translate_title":"SciBase Holding AB宣布与Castle Biosciences合作的临床研究初始订单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":0.9},"content_text":"SciBase Holding AB Announces Initial Order for Clinical Study in Collaboration with Castle Biosciences\n\n\n        SciBase Holding AB announced that it has received an initial order for a clinical study from Castle Biosciences. This development follows a collaboration and license agreement between the two companies, which was announced on June 16, 2025. The collaboration aims to develop a test for predicting flares in patients with atopic dermatitis. The order pertains to products intended for use in the clinical study of this project, with deliveries set to commence in the fourth quarter. Castle Biosciences has also invested in SciBase, becoming its second largest shareholder. SciBase CEO Pia Renaudin expressed the company's enthusiasm for advancing the project in collaboration with Castle Biosciences.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20250922:BIT:1083:0) on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}